The
Young Law Firm, a leading national shareholder litigation firm, is
investigating possible claims concerning the proposed acquisition
of Hi-Tech
Pharmacal Co., Inc. by Akorn,
Inc. The investigation concerns whether the directors of Hi-Tech
Pharmacal have obtained fair value for the sale of the Company and have
fulfilled their fiduciary duties to the Company’s shareholders in
connection with the proposed sale.
Pursuant to the terms of the proposed transaction, shareholders of Hi-Tech
Pharmacal Co., Inc. (Nasdaq: HITK)
will receive $43.50 per share in cash. The transaction is valued at
approximately $640 million.
Individual shareholders have rights. The Young Law Firm is seeking
active and engaged shareholders interested in ensuring that their rights
are being protected. If you own shares of the Company and would like to learn
more about the buyout of Hi-Tech Pharmacal, or have information
about the proposed transaction, please contact:
Henry Young Esq.
The
Young Law Firm
Toll Free: (888) 452-7252
Email:
contact@theyounglf.com
or
visit: www.mergersbuyoutsandfraud.com/hitech-pharmacal-buyout-merger-shareholder-lawsuit-hitk/
Henry Young Esq., the Firm’s founder, has over 10 years of experience
litigating complex shareholder class action lawsuits, including cases
resulting in the recovery of millions of dollars for shareholders. The
Firm routinely works with and refers cases to other leading law firms
around the country to enforce shareholder rights. For more information
about the Firm and class action cases in general, please visit our
website: www.theyounglf.com.
This press release may be considered attorney advertising. Past results
do not guarantee future performance.
Copyright Business Wire 2013